Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study will test the use of comprehensive ablative radiation therapy (CART), with and
without the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has
progressed after treatment and cannot be removed with surgery. The study researchers want to
find out whether CART works better when is given with avelumab than it does when given alone
to prevent the cancer from getting worse.